To determine the efficacy of the neuro protctant NA-1 in reducing global disability in subjects with AIS with a small established infarct core and good collateral circulation selected for EVT.
The study is currently actively recruiting at multiple international sites!
An international multidisciplinary survey to examine decisions in EVT care across the world. What factors govern the selection for EVT in the real-world.
To demonstrate the efficacy of using TNK-tPA to treat minor ischemic stroke in proven arterial occlusion.
A Phase 3, prospective, randomized controlled, open-‐label with blinded outcome assessment (PROBE) controlled trial.
Establish the safety of early anticoagulation with the novel oral anticoagulant dabigatran in acute cerebrovascular syndrome patients.
Identify the rate of both symptomatic and asymptomatic hemorrhagic transformation (HT) associated with these treatments.
Identify predictors of HT associated with acute dabigatran treatment.
Hypothesis: The Investigators hypothesize that symptomatic HT rates in dabigatran and ASA treated patients will not be significantly different.
A multicenter randomized, double blind placebo controlled trial to determine the efficacy of long-term, low dose warfarin in the secondary prevention of venous thromboembolism.